EAU 2023 - The 38th Annual European Association of Urology Congress 2023
Mar 10 - Mar 13, 2023 | MilanItaly
LARVOL is not affiliated with The 38th Annual European Association of Urology Congress 2023 and all trademarks, logos, and brand names are property of their respective owners
Showing 79 abstracts linked to Trials
LuTectomy: a prospective study of dosimetry, safety and potential benefit of upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with high-risk localized prostate cancer
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma - results from phase 3 ZIRCON study
Quality of life with open vs robotic-assisted partial nephrectomy (OpeRa) in patients with intermediate/high-complexity renal tumours: Presenter
How should lesions without anatomical correspondence in 18F-PSMA-1007 PET/CT be interpreted - a PROSTAGE follow-up study
Orgasmic function worsening could lead to erectile function decrease after holep – Results from a prospective trial (expho)
Holmium Laser Enucleation of the Prostate is associated with complications and sequelae even in the hands of an experienced surgeon. Results from a prospective series
Finals results in the safety and performance evaluation of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer
Salvage radical prostatectomy following 177Lu-PSMA-617 radioligand therapy in men with high-risk localized prostate cancer: surgical aspects of the LuTectomy study
68Ga-PSMA-PET/CT in patients starting on Active Surveillance for PRostate cancer - Trial (PASPoRT)
MRI-guided Active Surveillance without annual re-biopsy in patients with ISUP 1 and 2 prostate cancer – The prospective PROMM-AS Study
Four-year follow-up of MRI-guided transurethral ultrasound ablation (TULSA) in men with localized prostate cancer
Salvage transurethral ultrasound ablation (TULSA) for localized radio-recurrent prostate cancer: 12-month safety and oncological outcomes
12-month clinical outcomes of MRI-guided transurethral ultrasound ablation for localized prostate cancer
Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: experience from the first study on clinical efficacy
Transperineal targeted microwave ablation for low to intermediate-risk prostate cancer: results of a phase I-II study (NCT04627896)